Effect of L. Reuteri LM1063 on Sleep Health Improvement

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Sleep Quality, Sleep Wake Disorders

In brief

Purpose: The purpose of this clinical trial is to evaluate the efficacy and safety of Limosilactobacillus reuteri LM1063 on improving sleep health in healthy adults. Based on the microbiota-gut-brain axis, this study aims to scientifically analyze whether the supplementation of this specific probiotic strain can enhance sleep quality. Methodology: This is a randomized, double-blind, placebo-controlled, single-center clinical trial. A total of 80 participants (40 in the test group and 40 in the control group) will be enrolled. Participants in the test group will consume 500 mg of L. reuteri LM1063 (1.0 x 10\^10 CFU/day) once daily for 8 weeks, while the control group will receive a placebo. Key Evaluations: To assess sleep improvement, various parameters will be measured before and after the 8-week intake period: * Primary Outcomes: Polysomnography (PSG) measures including sleep efficiency (SE), sleep latency (SL), total sleep time (TST), wake after sleep onset (WASO), and delta power; and the Pittsburgh Sleep Quality Index (PSQI). * Secondary Outcomes: Various sleep and stress-related scales (SSS, ESS, PSS, RSQ-W, FSS) and blood biomarkers such as melatonin, GABA, and serotonin levels. * Safety: Monitored through adverse events, vital signs, and clinical laboratory tests.

Key facts

Study ID

NCT07498712

Run by

Lactomason Co., Ltd.

People needed

80

Starts

2025-07-14

Expected to finish

2026-06-30

Last updated by the study team

2026-03-27

Who can join

Age: 19 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male or female adults aged 19 to 65.
• Pittsburgh Sleep Quality Index (PSQI) score of 5 or higher.
• Voluntarily agreed to participate and signed the informed consent form.

You may not qualify if…

• Severe sleep disorders (Insomnia Severity Index ≥ 22 or ≤ 7).
• Medical conditions causing sleep disorders (Sleep apnea, Restless legs syndrome, Depression, Narcolepsy, etc.).
• Intake of medications affecting sleep within 1 month before the first visit.
• Intake of probiotics or fermented milk products within 1 month before the first visit.

Where it is running

• P&K Skin Research Center — Seoul, Yeongdeungpo, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.